{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:01:43Z","timestamp":1769634103915,"version":"3.49.0"},"reference-count":26,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,5,1]]},"abstract":"<jats:p>Objective. To determine the efficacy of tolazoline as a rescue treatment for hypoxemia in preterm infants with respiratory distress syndrome.<\/jats:p><jats:p>Methods. Retrospective chart review on case series of infants weighing &amp;lt;750 g at birth who received tolazoline during a severe hypoxemic episode while receiving maximal ventilator support for respiratory distress syndrome. A slow bolus infusion of low dose tolazoline (0.5 mg\u20132 mg\/kg) mixed with plasmanate or normal saline (10 mL\/kg) was administered. Outcome measures evaluated included an increase in Pao2 \u226520 mm Hg from pretreatment value and an increase in oxygen saturation to \u226590%.<\/jats:p><jats:p>Results. Forty-three infants with a mean gestational age and birth weight of 24 weeks and 581 g, respectively, received tolazoline. All infants were mechanically ventilated and required a fraction of inspired oxygen of 1.0. Oxygenation improved in 72% (31\/43) of infants with a tolazoline dose of 0.5 to 1.0 mg\/kg. Of those who responded, Pao2 values (mean \u00b1 standard deviation) pretolazoline and posttolazoline were 32 \u00b1 7.5 mm Hg and 156 \u00b1 114.9 mm Hg, respectively. In all responders, oxygen saturation increased to \u226590% within 30 minutes of tolazoline administration. Improvement in pH, pCO2, oxygenation index, and mean airway pressure was also noted. Among nonresponders, pH decreased and pCO2 increased after tolazoline. Minimal change in blood pressure was noted in both responders and nonresponders. Heart rate decreased by 19 beats per minute among nonresponders compared with an increase of 3 beats per minute in those who responded to tolazoline.<\/jats:p><jats:p>Conclusion. Tolazoline is an effective treatment of severe resistant hypoxemia in preterm infants who are already on vigorous ventilatory support.<\/jats:p>","DOI":"10.1542\/peds.109.5.852","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:17:55Z","timestamp":1092442675000},"page":"852-856","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and Safety of Tolazoline for Treatment of Severe Hypoxemia in Extremely Preterm Infants"],"prefix":"10.1542","volume":"109","author":[{"given":"Pracha","family":"Nuntnarumit","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheldon B.","family":"Korones","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjian","family":"Yang","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrietta S.","family":"Bada","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2002,5,1]]},"reference":[{"key":"2021121006292413400_R1","unstructured":"Ahlquist RP, Huggins RA, Woodbury RA. The pharmacology of benzylimidazoline (priscol).J Pharmacol Exp Ther.1947;89:271\u2013288"},{"key":"2021121006292413400_R2","unstructured":"Korones SB, Eyal FG. Successful treatment of persistent fetal circulation with tolazoline [abstract].Pediatr Res.1975;9:367"},{"key":"2021121006292413400_R3","doi-asserted-by":"crossref","unstructured":"Goetzman BW, Sunshine P, Johnson JD, et al. Neonatal hypoxia and pulmonary vasospasm: response to tolazoline.J Pediatr.1976;89:617\u2013621","DOI":"10.1016\/S0022-3476(76)80403-9"},{"key":"2021121006292413400_R4","doi-asserted-by":"crossref","unstructured":"Stevens DC, Schreiner RL, Bull MJ, et al. An analysis of tolazoline therapy in the critically ill neonates.J Pediatr Surg.1980;15:964\u2013970","DOI":"10.1016\/S0022-3468(80)80311-3"},{"key":"2021121006292413400_R5","doi-asserted-by":"crossref","unstructured":"Stevenson DK, Kasting DS, Darnall RA, et al. Refractory hypoxemia associated with neonatal pulmonary disease: the use and limitation of tolazoline.J Pediatr.1979;95:595\u2013599","DOI":"10.1016\/S0022-3476(79)80777-5"},{"key":"2021121006292413400_R6","doi-asserted-by":"crossref","unstructured":"Dillard RG. Fatal gastrointestinal hemorrhage in a neonate treated with tolazoline.Clin Pediatr.1982;21:761\u2013762","DOI":"10.1177\/000992288202101214"},{"key":"2021121006292413400_R7","doi-asserted-by":"crossref","unstructured":"Wilson RG, George RJ, McCormick WJ, Raine PAM. Duodenal perforation associated with tolazoline.Arch Dis Child.1985;60:878\u2013879","DOI":"10.1136\/adc.60.9.878"},{"key":"2021121006292413400_R8","doi-asserted-by":"crossref","unstructured":"Evans NJ, Archer LNJ. Doppler assessment of pulmonary pressure and extrapulmonary shunting in the acute phase of hyaline membrane disease.Arch Dis Child.1991;66:6\u201311","DOI":"10.1136\/adc.66.1_Spec_No.6"},{"key":"2021121006292413400_R9","doi-asserted-by":"crossref","unstructured":"Skinner JR, Boys RJ, Hunter S, Ney EN. Pulmonary and systemic arterial pressure in hyaline membrane disease.Arch Dis Child.1992;67:366\u2013373","DOI":"10.1136\/adc.67.4_Spec_No.366"},{"key":"2021121006292413400_R10","doi-asserted-by":"crossref","unstructured":"Walther FJ, Benders MJ, Leighton JO. Persistent pulmonary hypertension in preterm neonates with severe respiratory distress syndrome.Pediatrics.1992;90:899\u2013904","DOI":"10.1542\/peds.90.6.899"},{"key":"2021121006292413400_R11","doi-asserted-by":"crossref","unstructured":"Golan A, Zaizstein E, Zmora E, Shinwell ES. Pulmonary hypertension in respiratory distress syndrome.Pediatr Pulmonol.1995;19:221\u2013225","DOI":"10.1002\/ppul.1950190406"},{"key":"2021121006292413400_R12","unstructured":"Sanders J, Miller DD, Patil PN. Alpha adrenergic and histaminergic effects of tolazoline-like imidazolines.J Pharmacol Exp Ther.1975;195:362\u2013371"},{"key":"2021121006292413400_R13","doi-asserted-by":"crossref","unstructured":"Zavecz JH, Yellin TO. Interaction of alpha adrenergic imidazoline with cardiac histamine H2 receptors.Eur J Pharmacol.1981;71:297\u2013306","DOI":"10.1016\/0014-2999(81)90032-7"},{"key":"2021121006292413400_R14","doi-asserted-by":"crossref","unstructured":"Ward RM. Pharmacology of tolazoline.Clin Perinatol.1984;11:703\u2013713","DOI":"10.1016\/S0095-5108(18)30912-6"},{"key":"2021121006292413400_R15","doi-asserted-by":"crossref","unstructured":"Goetzman BW, Milstein JM. Pulmonary vasodilator action of tolazoline.Pediatr Res.1979;13:942\u2013944","DOI":"10.1203\/00006450-197908000-00014"},{"key":"2021121006292413400_R16","doi-asserted-by":"crossref","unstructured":"Bush A, Busst CM, Knight WB, Shinebourne EA. Cardiovascular effects of tolazoline and ranitidine.Arch Dis Child.1987;62:241\u2013246","DOI":"10.1136\/adc.62.3.241"},{"key":"2021121006292413400_R17","doi-asserted-by":"crossref","unstructured":"Cotton EK. The use of priscoline in the treatment of the hypoperfusion syndrome.Pediatrics.1965;36:149","DOI":"10.1542\/peds.36.1.149"},{"key":"2021121006292413400_R18","doi-asserted-by":"crossref","unstructured":"McIntosh N, Walters RO. Effect of tolazoline in severe hyaline membrane disease.Arch Dis Child.1979;54:105\u2013110","DOI":"10.1136\/adc.54.2.105"},{"key":"2021121006292413400_R19","doi-asserted-by":"crossref","unstructured":"Ward RM, Daniel CH, Kendig JW, Wood MA. Oliguria and tolazoline pharmacokinetics in the newborn.Pediatrics.1986;77:307\u2013315","DOI":"10.1542\/peds.77.3.307"},{"key":"2021121006292413400_R20","unstructured":"Ward RM, Daniel CH, Willes SR, Gallaher KJ. Tolazoline pharmacokinetics in lambs.Pediatr Pharmacol.1984;4:101\u2013107"},{"key":"2021121006292413400_R21","doi-asserted-by":"crossref","unstructured":"Monin P, Dubruc C, Vert P, Morselli PL. Treatment of persistent fetal circulation syndrome of the newborn, comparison of different doses of tolazoline.Eur J Clin Pharmacol.1987;31:569\u2013573","DOI":"10.1007\/BF00606632"},{"key":"2021121006292413400_R22","doi-asserted-by":"crossref","unstructured":"Monin P, Vert P, Morselli PL. A pharmacodynamic and pharmacokinetic study of tolazoline in the neonate.Dev Pharmacol Ther.1982;4:124\u2013128","DOI":"10.1159\/000457367"},{"key":"2021121006292413400_R23","doi-asserted-by":"crossref","unstructured":"Nuntnarumit P, Bada HS, Yang W, et al. Relationship of neurobiologic risk score and neurodevelopmental outcome in extremely low birth weight (ELBW) infants [abstract].Pediatr Res.1998;43:224A","DOI":"10.1203\/00006450-199804001-01328"},{"key":"2021121006292413400_R24","doi-asserted-by":"crossref","unstructured":"Ferrara TB, Hoekstra RE, Couser RJ, et al. Survival and follow-up of infants born at 23 to 26 weeks of gestational age; effects of surfactant therapy.J Pediatr.1994;124:119\u2013124","DOI":"10.1016\/S0022-3476(94)70266-7"},{"key":"2021121006292413400_R25","doi-asserted-by":"crossref","unstructured":"Allen MC, Donohue PK, Dusman AE. The limit of viability-neonatal outcome of infants born at 22 to 25 weeks\u2019 gestation.N Engl J Med.1993;329:1597\u20131601","DOI":"10.1056\/NEJM199311253292201"},{"key":"2021121006292413400_R26","doi-asserted-by":"crossref","unstructured":"Meadow W, Benn A, Giardini N, Hageman J, Berger S. Clinical correlates do not predict Pao2 response after tolazoline administration in hypoxic newborns.Crit Care Med.1986;14:548\u2013551","DOI":"10.1097\/00003246-198606000-00006"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/5\/852\/1114974\/pe0502000852.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/5\/852\/1114974\/pe0502000852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:37:07Z","timestamp":1682746627000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/109\/5\/852\/64289\/Efficacy-and-Safety-of-Tolazoline-for-Treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,1]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2002,5,1]]},"published-print":{"date-parts":[[2002,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.109.5.852","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,1]]}}}